Canagliflozin 100 mg vs 300 mg: What a New Kidney and Heart Outcomes Analysis Found 10th August 2026 by Living Diabetes Editorial A post hoc CANVAS analysis found no clear kidney or cardiovascular advantage for canagliflozin 300 mg over 100 mg, but the findings are hypothesis-generating rather than definitive.